title: Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum.
abstract: Nitrergic nerves and endothelial cells release nitric oxide (NO) in the corpus cavernosum, a key mediator that stimulates soluble guanylyl cyclase to increase cGMP levels causing penile erection. Phosphodiesterase 5 (PDE5) inhibitors, such as sildenafil, prolong the NO effects by inhibiting cGMP breakdown. Here, we report a novel PDE5 inhibitor, lodenafil carbonate, (Bis-(2-{4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-benzenesulfonyl]piperazin-1-yl}-ethyl)carbonate) that is a dimer of lodenafil. We therefore aimed to compare the effects of sildenafil, lodenafil and lodenafil carbonate on in vitro human and rabbit cavernosal relaxations, activity of crude PDE extracts from human platelets, as well as stability and metabolic studies in rat, dog and human plasma. Pharmacokinetic evaluations after intravenous and oral administration were performed in male beagles. Functional experiments were conducted using organ bath techniques. Pharmacokinetics was studied in beagles by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), following oral or intravascular administration. All PDE5 inhibitors tested concentration-dependently relaxed (0.001-100 microM) phenylephrine-precontracted rabbit and human corpus cavernosum. The cavernosal relaxations evoked by either acetylcholine (0.01-100 microM) or electrical field stimulation (EFS, 1-20 Hz) were markedly potentiated by sildenafil, lodenafil and lodenafil carbonate. Lodenafil carbonate was more potent to inhibit the cGMP hydrolysis in PDE extracts compared with lodenafil and sildenafil. Following intravascular and single oral administration of lodenafil carbonate, only lodenafil and norlodenafil were detected in vivo. These results indicate that lodenafil carbonate works as a prodrug, being lodenafil the active moiety of lodenafil carbonate.
authors.affiliation: Department of Pharmacology, UNICAMP, Campinas, SP, 13081-970, Brazil.
authors.forename: Haroldo A
authors.initials: HA
authors.lastname: Toque
authors.forename: Cleber E
authors.initials: CE
authors.lastname: Teixeira
authors.forename: Raquel
authors.initials: R
authors.lastname: Lorenzetti
authors.forename: Cristina E
authors.initials: CE
authors.lastname: Okuyama
authors.forename: Edson
authors.initials: E
authors.lastname: Antunes
authors.forename: Gilberto
authors.initials: G
authors.lastname: De Nucci
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000818:Animals; D002254:Carbonates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D002853:Chromatography, Liquid; D006152:Cyclic GMP / Q000378:metabolism; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D004558:Electric Stimulation; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010413:Penis / Q000187:drug effects* / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D010879:Piperazines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011355:Prodrugs; D011687:Purines / Q000494:pharmacology; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000494:pharmacology; D053719:Tandem Mass Spectrometry
chemical_list: D002254:Carbonates; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011355:Prodrugs; D011687:Purines; D011743:Pyrimidines; D013450:Sulfones; C532120:lodenafil carbonate; D000068677:Sildenafil Citrate; D006152:Cyclic GMP